UK has secured 407 million doses of vaccine - here's a rundown
Confirmation the UK has secured another 40 million doses of French vaccine candidate Valneva brings the total ordered to 407 million.
Here are the vaccines the UK has access to:
BioNTech/Pfizer
Doses: 40 million - enough for 20 million people.
The vaccine was approved for use on 2 December.
Oxford/AstraZeneca
Doses: 100 million - enough for 50 million people.
The jab got the green light from the MHRA on 30 December.
Moderna
Doses: 17 million - enough for 8.5 million people.
The jab from the US biotech firm has also been approved for use but doses will not be available until the spring.
Novavax
Doses: UK has secured 60 million doses.
Novavax is running a phase three clinical trial in the UK, and plans to manufacture its vaccine in the UK with Fujifilm Diosynth Biotechnologies.
Results from those trials show the vaccine offers 89% protection.
Janssen
Doses: 30 million doses have been secured from Janssen, which is owned by Johnson & Johnson.
Results from clinical studies show the jab is 66% effective overall. Deliveries are expected in the second half of 2021, should it receive approval from the MHRA.
Valneva
Doses: Pending approval, the original order for 60 million is set for delivery in the second half of this year and now the option for a second batch of 40 million doses has been triggered. These have been earmarked for delivery in 2022.
Valneva's site in Livingston, West Lothian, will manufacture the vaccine.
GlaxoSmithKline (GSK) and Sanofi Pasteur
Doses: 60 million.
Interim results of early phases of trials show an immune response comparable to patients who recovered from COVID in adults aged 18 to 49 years, but a low immune response in older adults.
Confirmation the UK has secured another 40 million doses of French vaccine candidate Valneva brings the total ordered to 407 million.
Here are the vaccines the UK has access to:
BioNTech/Pfizer
Doses: 40 million - enough for 20 million people.
The vaccine was approved for use on 2 December.
Oxford/AstraZeneca
Doses: 100 million - enough for 50 million people.
The jab got the green light from the MHRA on 30 December.
Moderna
Doses: 17 million - enough for 8.5 million people.
The jab from the US biotech firm has also been approved for use but doses will not be available until the spring.
Novavax
Doses: UK has secured 60 million doses.
Novavax is running a phase three clinical trial in the UK, and plans to manufacture its vaccine in the UK with Fujifilm Diosynth Biotechnologies.
Results from those trials show the vaccine offers 89% protection.
Janssen
Doses: 30 million doses have been secured from Janssen, which is owned by Johnson & Johnson.
Results from clinical studies show the jab is 66% effective overall. Deliveries are expected in the second half of 2021, should it receive approval from the MHRA.
Valneva
Doses: Pending approval, the original order for 60 million is set for delivery in the second half of this year and now the option for a second batch of 40 million doses has been triggered. These have been earmarked for delivery in 2022.
Valneva's site in Livingston, West Lothian, will manufacture the vaccine.
GlaxoSmithKline (GSK) and Sanofi Pasteur
Doses: 60 million.
Interim results of early phases of trials show an immune response comparable to patients who recovered from COVID in adults aged 18 to 49 years, but a low immune response in older adults.